|
1
|
Gibbs AR: Role of asbestos and other
fibres in the development of diffuse malignant mesothelioma.
Thorax. 45:649–654. 1990. View Article : Google Scholar
|
|
2
|
Bibby AC, Tsim S, Kanellakis N, Ball H,
Talbot DC, Blyth KG, Maskell NA and Psallidas I: Malignant pleural
mesothelioma: An update on investigation, diagnosis and treatment.
Eur Respir Rev. 25:472–486. 2016. View Article : Google Scholar
|
|
3
|
Marinaccio A, Binazzi A, Marzio DD,
Scarselli A, Verardo M, Mirabelli D, Gennaro V, Mensi C, Riboldi L,
Merler E, et al: Pleural malignant mesothelioma epidemic:
Incidence, modalities of asbestos exposure and occupations involved
from the Italian national register. Int J Cancer. 130:2146–2154.
2012. View Article : Google Scholar
|
|
4
|
Robinson BW: Malignant pleural
mesothelioma: An epidemiological perspective. Ann Cardiothorac
Surg. 1:491–496. 2012.
|
|
5
|
Yap TA, Aerts JG, Popat S and Fennell DA:
Novel insights into mesothelioma biology and implications for
therapy. Nat Rev Cancer. 17:475–488. 2017. View Article : Google Scholar
|
|
6
|
Pass HI, Alimi M, Carbone M, Yang H and
Goparaju CM: Mesothelioma biomarkers: A review highlighting
contributions from the early detection research network. Cancer
Epidemiol Biomarkers Prev. Jul 22–2020.(Epub ahead of print). doi:
10.1158/1055-9965.EPI-20-0083. View Article : Google Scholar
|
|
7
|
Billé A, Krug LM, Woo KM, Rusch VW and
Zauderer MG: Contemporary analysis of prognostic factors in
patients with unresectable malignant pleural mesothelioma. J Thorac
Oncol. 11:249–255. 2016. View Article : Google Scholar
|
|
8
|
Linton A, Pavlakis N, O'Connell R, Soeberg
M, Kao S, Clarke S, Vardy J and van Zandwijk N: Factors associated
with survival in a large series of patients with malignant pleural
mesothelioma in new south Wales. Br J Cancer. 111:1860–1869. 2014.
View Article : Google Scholar
|
|
9
|
Røe OD: Mesothelioma diagnosis and
prognosis, are we moving beyond histology and performance status
towards circulating biomarkers? J Thorac Dis. 10 (Suppl
17):S1956–S1961. 2018. View Article : Google Scholar
|
|
10
|
Jean D, Daubriac J, Le Pimpec-Barthes F,
Galateau-Salle F and Jaurand MC: Molecular changes in mesothelioma
with an impact on prognosis and treatment. Arch Pathol Lab Med.
136:277–293. 2012. View Article : Google Scholar
|
|
11
|
Bueno R, Stawiski EW, Goldstein LD,
Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS,
Chirieac LR, et al: Comprehensive genomic analysis of malignant
pleural mesothelioma identifies recurrent mutations, gene fusions
and splicing alterations. Nat Genet. 48:407–416. 2016. View Article : Google Scholar
|
|
12
|
Lo Russo G, Tessari A, Capece M, Galli G,
de Braud F, Garassino MC and Palmieri D: MicroRNAs for the
diagnosis and management of malignant pleural mesothelioma: A
literature review. Front Oncol. 8:6502018. View Article : Google Scholar
|
|
13
|
Cavallari I, Urso L, Sharova E, Pasello G
and Ciminale V: Liquid biopsy in malignant pleural mesothelioma:
State of the art, pitfalls, and perspectives. Front Oncol.
9:7402019. View Article : Google Scholar
|
|
14
|
Arnold DT, De Fonseka D, Hamilton FW,
Rahman NM and Maskell NA: Prognostication and monitoring of
mesothelioma using biomarkers: A systematic review. Br J Cancer.
116:731–741. 2017. View Article : Google Scholar
|
|
15
|
Ferro P, Canessa PA, Battolla E, Dessanti
P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R,
Fedeli F, et al: Mesothelin is more useful in pleural effusion than
in serum in the diagnosis of pleural mesothelioma. Anticancer Res.
33:2707–2713. 2013.
|
|
16
|
Fontana V, Vigani A, Pistillo MP, Giannoni
U, Rosemberg I, Canessa PA, Berisso G, Ferro P, Franceschini M,
Tonarelli M and Roncella S: The correlation of serum mesothelin
level with pleural thickness in malignant pleural mesothelioma
makes it a valuable tool for monitoring tumor progression. J Thorac
Oncol. 14:e92–e94. 2019. View Article : Google Scholar
|
|
17
|
Luo L, Shi HZ, Liang QL, Jiang J, Qin SM
and Deng JM: Diagnostic value of soluble mesothelin-related
peptides for malignant mesothelioma: A meta-analysis. Respir Med.
104:149–156. 2010. View Article : Google Scholar
|
|
18
|
Schneider J, Hoffmann H and Dienemann H,
Herth FJ, Meister M, Muley T and Dienemann H: Diagnostic and
prognostic value of soluble mesothelin-related proteins in patients
with malignant pleural mesothelioma in comparison with benign
asbestosis and lung cancer. J Thorac Oncol. 3:1317–1324. 2008.
View Article : Google Scholar
|
|
19
|
Chang K and Pastan I: Molecular cloning of
mesothelin, a differentiation antigen present on mesothelium,
mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA.
93:136–140. 1996. View Article : Google Scholar
|
|
20
|
Lv J and Li P: Mesothelin as a biomarker
for targeted therapy. Biomark Res. 7:182019. View Article : Google Scholar
|
|
21
|
Morello A, Sadelain M and Adusumilli PS:
Mesothelin-targeted CARs: Driving T cells to solid tumors. Cancer
Discov. 6:133–146. 2016. View Article : Google Scholar
|
|
22
|
Hassan R, Thomas A, Alewine C, Le DT,
Jaffee EM and Pastan I: Mesothelin immunotherapy for cancer: Ready
for prime time? J Clin Oncol. 34:4171–4179. 2016. View Article : Google Scholar
|
|
23
|
Creaney J, Francis RJ, Dick IM, Musk AW,
Robinson BW, Byrne MJ and Nowak AK: Serum soluble mesothelin
concentrations in malignant pleural mesothelioma: Relationship to
tumor volume, clinical stage and changes in tumor burden. Clin
Cancer Res. 17:1181–1189. 2011. View Article : Google Scholar
|
|
24
|
Grigoriu BD, Scherpereel A, Devos P,
Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC
and Lassalle P: Utility of osteopontin and serum mesothelin in
malignant pleural mesothelioma diagnosis and prognosis assessment.
Clin Cancer Res. 13:2928–2935. 2007. View Article : Google Scholar
|
|
25
|
Cristaudo A, Foddis R, Vivaldi A,
Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M,
Ivaldi GP, et al: Clinical significance of serum mesothelin in
patients with mesothelioma and lung cancer. Clin Cancer Res.
13:5076–5081. 2007. View Article : Google Scholar
|
|
26
|
Dipalma N, Luisi V, Di Serio F, Fontana A,
Maggiolini P, Licchelli B, Mera E, Bisceglia L, Galise I, Loizzi M,
et al: Biomarkers in malignant mesothelioma: Diagnostic and
prognostic role of soluble mesothelin-related peptide. Int J Biol
Markers. 26:160–165. 2011. View Article : Google Scholar
|
|
27
|
Grigoriu BD, Chahine B, Vachani A, Gey T,
Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM and
Scherpereel A: Kinetics of soluble mesothelin in patients with
malignant pleural mesothelioma during treatment. Am J Respir Crit
Care Med. 179:950–954. 2009. View Article : Google Scholar
|
|
28
|
Creaney J, Yeoman D, Naumoff LK, Hof M,
Segal A, Musk AW, De Klerk N, Horick N, Skates SJ and Robinson BW:
Soluble mesothelin in effusions: A useful tool for the diagnosis of
malignant mesothelioma. Thorax. 62:569–576. 2007. View Article : Google Scholar
|
|
29
|
Linch M, Gennatas S, Kazikin S, Iqbal J,
Gunapala R, Priest K, Severn J, Norton A, Ayite B, Bhosle J, et al:
A serum mesothelin level is a prognostic indicator for patients
with malignant mesothelioma in routine clinical practice. BMC
Cancer. 14:6742014. View Article : Google Scholar
|
|
30
|
Tian L, Zeng R, Wang X, Shen C, Lai Y,
Wang M and Che G: Prognostic significance of soluble mesothelin in
malignant pleural mesothelioma: A meta-analysis. Oncotarget.
8:46425–46435. 2017. View Article : Google Scholar
|
|
31
|
Pass HI, Goparaju C, Espin-Garcia O,
Donington J, Carbone M, Patel D, Chen Z, Feld R, Cho J, Gadgeel S,
et al: Plasma biomarker enrichment of clinical prognostic indices
in malignant pleural mesothelioma. J Thorac Oncol. 11:900–909.
2016. View Article : Google Scholar
|
|
32
|
Hollevoet K, Nackaerts K, Thas O, Thimpont
J, Germonpré P, De Vuyst P, Bosquée L, Legrand C, Kellen E, Kishi
Y, et al: The effect of clinical covariates on the diagnostic and
prognostic value of soluble mesothelin and megakaryocyte
potentiating factor. Chest. 141:477–484. 2012. View Article : Google Scholar
|
|
33
|
Ak G, Tada Y, Shimada H, Metintas S, Ito
M, Hiroshima K, Tagawa M and Metintas M: Midkine is a potential
novel marker for malignant mesothelioma with different prognostic
and diagnostic values from mesothelin. BMC Cancer. 17:2122017.
View Article : Google Scholar
|
|
34
|
Creaney J, Dick IM, Meniawy TM, Leong SL,
Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, et al:
Comparison of fibulin-3 and mesothelin as markers in malignant
mesothelioma. Thorax. 69:895–902. 2014. View Article : Google Scholar
|
|
35
|
Marubini E and Valsecchi MG: Analyzing
Survival Data from Clinical Trials and Observational Studies. John
Wiley and Sons; New York, NY: 1995
|
|
36
|
Harrell FE Jr: Regression modelling
strategies. 2nd edition. Springer Verlag; New York, NY: pp. 22–28.
2015
|
|
37
|
Walters J and Maskell NA: Biopsy
techniques for the diagnosis of mesothelioma. Recent Results Cancer
Res. 189:45–55. 2011. View Article : Google Scholar
|
|
38
|
Tsao MS, Carbone M, Galateau-Salle F,
Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA,
Gomez D, et al: Pathologic considerations and standardization in
mesothelioma clinical trials. J Thorac Oncol. 14:1704–1717. 2019.
View Article : Google Scholar
|
|
39
|
Galateau Salle F, Le Stang N, Nicholson
AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud
JM, Attanoos R, et al: New insights on diagnostic reproducibility
of biphasic mesotheliomas: A multi-institutional evaluation by the
international mesothelioma panel from the MESOPATH reference
center. J Thorac Oncol. 13:1189–1203. 2018. View Article : Google Scholar
|
|
40
|
Fontana V, Pistillo MP, Vigani A, Canessa
PA, Berisso G, Giannoni U, Ferro P, Franceschini MC, Carosio R,
Tonarelli M, et al: Determination of mesothelin levels in pleural
effusion does not help predict survival of patients with malignant
pleural mesothelioma. Anticancer Res. 39:5219–5223. 2019.
View Article : Google Scholar
|
|
41
|
Creaney J, Yeoman D, Musk AW, de Klerk N,
Skates SJ and Robinson BW: Plasma versus serum levels of
osteopontin and mesothelin in patients with malignant
mesothelioma-which is best? Lung Cancer. 74:55–60. 2011. View Article : Google Scholar
|
